<DOC>
	<DOC>NCT00392288</DOC>
	<brief_summary>Primary objective: To demonstrate the efficacy of ciclesonide, compared to placebo, at 80 μg twice daily (BID) or 40 μg BID for 12 weeks in patients with persistent asthma. Secondary objective: To assess the safety and tolerability of ciclesonide.</brief_summary>
	<brief_title>Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Ciclesonide</mesh_term>
	<criteria>History of persistent bronchial asthma for at least 3 months prior to screening; For patients with persistent bronchial asthma and being treated with a controller therapy: Documented use of an inhaled steroid or Singulair® 5mg once daily; For patients with persistent bronchial asthma and not being treated with controller therapy: Patients may have documented use of a reliever therapy such as albuterol/salbutamol or may be untreated; Morning Peak Expiratory Flow (AM PEF) of ≤90% of predicted values from the inclinic spirometry after a 6 hour withhold of albuterol/salbutamol; Only patients aged between 6 to &lt;12 years must have a forced expiratory volume in one second (FEV1) of ≥50% to ≤85% of predicted normal after a 6 hour withhold of albuterol/salbutamol Nocturnal awakenings for asthma which require treatment with albuterol/salbutamol for 4 or more nights out of the last 7 days of the screening period; Use of more than 8 puffs/day of albuterol/salbutamol on 3 or more consecutive days within the last 7 Upper or lower respiratory tract infection within 4 weeks prior to screening and during screening period; History of lifethreatening asthma, including a history of significant hypercarbia (pCO2 &gt;45 mmHg), prior intubation, respiratory arrest, or seizures as a result of an exacerbation of asthma; More than 3 inpatient hospitalization or emergency care visits due to asthma exacerbations in the year prior to screening; Use of injectable or oral corticosteroids within one month prior to screening, or more than 3 bursts) within 6 months prior to screening;</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bronchial Asthma</keyword>
</DOC>